title: CD31 mismatching affects marrow transplantation outcome.
abstract: Graft-versus-host disease (GVHD) complicating allogeneic bone marrow transplantation (BMT) is often attributed to mismatched minor histocompatibility antigens (mHags), which are poorly defined in humans. CD31 is a candidate human mHag relevant to acute GVHD, but reports disagree about its level of significance, the role of HLA restriction, and the relative importance of different polymorphic codons within the molecule. We therefore examined in greater detail the impact of CD31-matching on BMT outcome in a prospective study from a single institution. Samples of recipient and donor DNA were collected pretransplantation for all patients receiving unmanipulated bone marrow from an HLA-identical sibling over a 45-month period at our institution. CD31 DNA typing of alleles at the 3 polymorphic codons 125 (L or V), 563 (N or S), and 670 (R or G) was performed for 118 patient-donor pairs plus 2 additional pairs who had codon 125 typing only. Donor-recipient CD31 nonidentity was tested for correlation with BMT clinical outcome measures of severe acute GVHD, chronic GVHD, relapse, and survival. Gene frequencies of approximately 0.5 for each allele at all 3 codons were comparable to previous reports. Because complete association was seen for 563N with 670G and for 563S with 670R, nonidentity for those codons was analyzed as a single genetic marker designated codon 563/670. Donor-recipient CD31 nonidentity was a significant risk factor for overall survival, both at codon 563/670 (hazard ratio [hr] = 2.58, P = .005) and at codon 125 (hr = 1.07, P = .036). Similar results held for disease-free survival. Nonidentity at codon 563/670 was also a significant risk factor (odds ratio [OR] = 11.15, P = .011) for severe (grades III, IV) versus no (grade 0) acute GVHD. Nonidentity at codon 125 posed less but still significant risk (OR = 9.30, P = .030). When the comparison group without severe acute GVHD was expanded to include grade I as well as grade 0 patients, the risk from CD31 nonidentity increased for both codon 563/670 (OR = 12.31, P = .010) and codon 125 (OR = 11.24, P = .011). CD31 nonidentity remained a significant independent risk factor for survival and for severe acute GVHD when tested in multivariate analysis with the covariates of adulthood, recipient-donor sex difference, ethnic group, disease, pretransplantation risk category, HLA-A2 type, B44-like types, and GVHD prophylactic regimen. CD31 nonidentity showed a trend but failed to achieve statistical significance as a risk factor for relapse and for chronic GVHD. In conclusion, donor-recipient CD31 nonidentity is a significant risk factor for survival and for severe acute GVHD in HLA-identical sibling BMT. The stronger associations with codon 563/670 suggest that polymorphism may be more important than the linked polymorphism at codon 125.
authors.affiliation: Department of Pathology, Stanford University, California, USA. grumet@stanford.edu
authors.forename: F C
authors.initials: FC
authors.lastname: Grumet
authors.forename: D D
authors.initials: DD
authors.lastname: Hiraki
authors.lastname: Brown BWM
authors.forename: J L
authors.initials: JL
authors.lastname: Zehnder
authors.forename: E S
authors.initials: ES
authors.lastname: Zacks
authors.forename: A
authors.initials: A
authors.lastname: Draksharapu
authors.forename: J
authors.initials: J
authors.lastname: Parnes
authors.forename: R S
authors.initials: RS
authors.lastname: Negrin
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000483:Alleles; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000706:statistics & numerical data; D002648:Child; D002908:Chronic Disease; D003062:Codon / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival / Q000276:immunology; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000209:etiology*; D006680:HLA Antigens / Q000032:analysis; D015235:HLA-B Antigens / Q000032:analysis; D059948:HLA-B44 Antigen; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D015993:Life Tables; D008297:Male; D015778:Minor Histocompatibility Antigens / Q000032:analysis* / Q000235:genetics; D015999:Multivariate Analysis; D009679:Nuclear Family; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000276:immunology* / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D003062:Codon; D006680:HLA Antigens; D015235:HLA-B Antigens; D059948:HLA-B44 Antigen; D015778:Minor Histocompatibility Antigens; D019408:Platelet Endothelial Cell Adhesion Molecule-1